Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

Amazon says the company will join other partners including United Parcel Service and the U.S. Postal Service that regularly work alongside Amazon's last-mile delivery network. The regulator's letter ...

Health-care companies rose sharply after President Trump signed an executive order designed to lower what Americans pay for prescription drugs that offered pharmaceutical companies room for ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

The Trump administration is pushing for reduced prices on weight-loss drugs like Wegovy and Zepbound, citing stark pricing ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...